@chris_practical's TRT gear test claims, fact-checked

What did @chris_practical actually say?

The video breaks down injectable testosterone compounds into three components: the hormone (the anabolic plus its ester), the carrier oil, and the excipients. Chris says MCT oil is the most common carrier, that ethyl oleate gets a bad reputation it may not deserve, and that guaiacol is the solvent he actually has a concern about. He closes by recommending viewers monitor hsCRP as a proxy for inflammation and promises a follow-up on gear testing methods.

This is a reasonably structured overview for a TikTok video aimed at people using or considering injectable testosterone compounds. The framing is practical rather than alarmist, which is a notable departure from how this topic usually circulates on social media. That said, some of the specifics deserve a closer look.

Does the science back this up?

Mostly, yes, with some important nuance. The three-component framing is accurate. Ethyl oleate is genuinely used as a pharmaceutical co-solvent and has been studied in compounded progesterone preparations. The fear around it is largely anecdotal and community-driven rather than evidence-based.

Ethyl oleate has been used in compounded progesterone formulations for over two decades. A 2014 review by Sitruk-Ware and colleagues in the journal Contraception noted its use as a co-solvent without flagging systemic toxicity concerns at low concentrations. The compound's safety profile in animal models is well established, and the European Medicines Agency has approved it as a pharmaceutical excipient. The claim that compounding pharmacies use it "pretty liberally" is consistent with published pharmacy literature on progesterone-in-oil injections.

Guaiacol is a different story. It is a phenolic solvent used in high-concentration injectable preparations, and unlike ethyl oleate, it has a documented irritation profile. Reports of post-injection pain and local inflammation with guaiacol-containing compounds appear in both the gray literature and in limited pharmacology studies. Chris is right to single it out.

The hsCRP recommendation is sound in principle. High-sensitivity C-reactive protein is a validated systemic inflammation marker used in cardiovascular risk stratification. Monitoring it in the context of injectable compounds that may contain irritating solvents is reasonable clinical thinking.

What did they get wrong (or right)?

The ethyl oleate section deserves credit. The community discourse around ethyl oleate tends toward the conspiratorial, and Chris pushes back on that appropriately. The line "I'm not saying seek it out, ideally avoid it if you can" is a fair harm-reduction stance rather than a blanket condemnation.

Where the video gets shaky is the phrase "you've actually never seen ethyl oleate beyond two percent." That specific threshold is not cited, and its source is unclear. Ethyl oleate concentrations in compounded preparations vary considerably. The FDA's Inactive Ingredient Database does not specify a universal upper limit for injectable formulations containing ethyl oleate, and published papers on compounded testosterone do not consistently use the two percent figure. This reads like community knowledge being presented as a pharmacological fact.

The dismissal of higher-concentration blends like "Sustanon 500" or "600 mg per mL" as problematic is directionally correct. Solubility limits for testosterone esters in carrier oils are well understood in pharmaceutical compounding, and concentrations exceeding roughly 250 mg per mL for single esters generally require additional solvents to stay in solution, which increases the risk of irritation or injection site reactions. Chris is right that these formulations are where solvent problems tend to cluster.

What should you actually know?

If you are on a prescribed TRT protocol through a licensed provider, the carrier oil and excipient composition of your testosterone preparation should already be disclosed on the product label or pharmacy compounding sheet. Carrier oil concerns are most relevant for people sourcing compounds from unregulated gray-market suppliers, where formulation consistency is not guaranteed.

hsCRP is a useful but non-specific inflammation marker. Elevations can reflect injection site irritation, systemic illness, cardiovascular stress, or a dozen other causes. It is not a direct test for solvent toxicity. Using it as a longitudinal tracker makes sense, but a single elevated reading should not be interpreted as proof of a solvent problem.

Guaiacol's irritation potential is real. If your injectable preparation lists guaiacol or cresol as an ingredient and you are experiencing significant post-injection pain, that is a conversation worth having with your prescribing clinician. Benzyl alcohol, the most common bacteriostatic agent in injectable preparations, has a well-characterized safety profile and is not in the same category as guaiacol.

The broader takeaway is that formulation quality matters and that not all injectable testosterone preparations are equivalent. Compounded products from licensed pharmacies operating under 503A or 503B regulations in the US are subject to quality standards. Products sourced outside that system are not, and the actual excipient content may differ from what is described.